» Articles » PMID: 35712263

Cannabis Use Increases the Risk of Sickness Absence: Longitudinal Analyses From the CONSTANCES Cohort

Overview
Specialty Public Health
Date 2022 Jun 17
PMID 35712263
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To examine the longitudinal associations between cannabis use and risks of short (<7 days), medium (7-28 days), and long (>28 days) sickness absences at one-year follow-up.

Methods: 87,273 participants aged 18-65 years from the French CONSTANCES cohort reported their frequency of cannabis use at inclusion between 2012 and 2018. Sickness absences occurring during one year of follow-up were collected from national medico-administrative registries. Multivariable generalized linear regressions were used to compute the Odds Ratios (OR) with their 95% Confidence Intervals (CI) of having at least one sickness absence at follow-up compared to no sickness absence, while controlling for sociodemographic factors, chronic conditions and occupational factors.

Results: Cannabis use more than once a month was associated with an increased risk of short (OR, [95% CI]: 1.56 [1.32-1.83]) and medium (1.29 [1.07-1.54]) sickness absences at one-year follow-up, with dose-dependent relationships for short sickness absences (1.13 [1.08-1.18], -for-trend <0.001). In stratified analyses, cannabis use was associated with an increased risk of sickness absences in older individuals, men, participants with good self-rated health, living or having lived as a couple, and having an open-ended contract.

Conclusions: Cannabis use prospectively increased the risk of short and medium sickness absences, even from once a month and with a dose-dependent relationship for short sickness absences. These findings should be considered in information and prevention public health campaigns to alert the general population and workers to this increased risk.

Citing Articles

Cannabis Use, Use Disorder, and Workplace Absenteeism in the U.S., 2021-2022.

Yang K, Mueller L, El-Shahawy O, Palamar J Am J Prev Med. 2024; 67(6):803-810.

PMID: 39186019 PMC: 11585432. DOI: 10.1016/j.amepre.2024.07.021.

References
1.
Ogborne A, Smart R, Weber T, Birchmore-Timney C . Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs. 2001; 32(4):435-43. DOI: 10.1080/02791072.2000.10400245. View

2.
Cerda M, Moffitt T, Meier M, Harrington H, Houts R, Ramrakha S . Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study. Clin Psychol Sci. 2016; 4(6):1028-1046. PMC: 5167539. DOI: 10.1177/2167702616630958. View

3.
Sexton M, Cuttler C, Finnell J, Mischley L . A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. Cannabis Cannabinoid Res. 2017; 1(1):131-138. PMC: 5549439. DOI: 10.1089/can.2016.0007. View

4.
Tompa E, Scott-Marshall H, Fang M . Social protection and the employment contract: the impact on work absence. Work. 2010; 37(3):251-60. DOI: 10.3233/WOR-2010-1077. View

5.
Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P . The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017; 26(8):954-962. DOI: 10.1002/pds.4233. View